Skip to main content
. 2021 May 6;13(5):1566. doi: 10.3390/nu13051566

Table 2.

Baseline characteristics of the three intervention groups (PP population).

200 mL 400 mL 600 mL p-Value
n 34 37 34
Age (months) 20.0, 8.5 20.0, 7.5 18.0, 8.5 0.48 °
Gender (boys/girls) (%) 47.1/52.9 51.4/48.6 38.2/61.8 0.53 #
Social class (upper/middle/lower) (%) 0.0/21.2/78.8 2.8/19.4/77.8 0.0/17.6/82.3 0.57 #
Religion (Muslim/Christian) (%) 72.7/27.3 63.9/36.1 70.6/29.4 0.71 #
Weight (kg) 9.2, 2.3 8,9, 1.1 8.7, 1.8 0.42 °
Height (cm) 78.9 ± 5.5 a 78.2 ± 4.8 a,b 75.8 ± 4.4 b 0.03 *
Weight for age Z-score −1.78 ± 0.60 −1.71 ± 0.55 −1.78 ± 0.54 0.84 *
Height for age Z-score −1.60 ± 0.61 −1.74 ± 0.53 −1.96 ± 0.62 0.06 *
Weight for height Z-score −1.34 ± 0.77 −1.15 ± 0.72 −1.07 ± 0.72 0.30 *
Hb (g/dL) 10.4, 0.8 10.1, 1.7 10.0, 1.6 0.08 °
Ferritin (µg/L) 37.6, 36.9 35.7, 46.9 38.2, 52.1 0.83 °
CRP (mg/L) 1.7, 5.6 2.1, 7.2 2.1, 4.8 0.60 °
Inflammation prevalence (%) 18.2 19.4 15.2 0.89 #
Vitamin B12 deficiency (%) 0.0 7.1 0.0 0.32 *
Folate deficiency (%) 9.1 8.0 21.1 0.40 *
Iodine (µg/L) 268.3, 405.7 327.6, 458.5 315.8, 467.5 0.99 °

Data are presented as median, IQR, percentages, or mean ± SD. Output of ° Kruskal–Wallis H test, # Chi-square test, or * one-way ANOVA. Different letters in superscript (a and b) indicate differences between treatment groups.